Pfizer                4Q Revenues: $14.0 billion (+2%) 4Q Loss: $394 million (earnings were $12.3 billion 4Q17) FY Revenues: $53.6 million (+2%) FY Earnings: $11.2 billion  (-48%) Comments: Innovative health sales were $8.9 million in the quarter, up 6% to $5.1 billion. Lyrica sales were up 8% to $1.2 billion in the quarter. Ibrance sales were $1.1 billion, up 58%. Eliquis revenues were $910 million, up 28%. Xeljanz sales were $553 million, up 35%. Prevenar 13 sales were down 1% to $1.5 bil...